Evidence map›Paper›PMID 31248414›Full record

ArticleMalaria journal2019

Asymptomatic malaria infections and Pfmdr1 mutations in an endemic area of Nigeria.

Titilope M Dokunmu, Cynthia U Adjekukor, Omolara F Yakubu, Adetutu O Bello, Jarat O Adekoya, Olugbenga Akinola, Emmanuel O Amoo, Abiodun H Adebayo

Open access · goldAbstract read
In one paragraph

Article in Malaria journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 2 pooled it
4.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 42 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Journal of parasitic diseases : official organ of the Indian Society for Parasitology · 2023
    Article
  15. Review
  16. Article
  17. Prevalence and temporal changes of mutations linked to antimalarial drug resistance in Plasmodium falciparum and Plasmodium vivax in Palawan, Philippines.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022
    Article
  18. Article
  19. Review
  20. Polymorphism Analysis ofDiseases (Basel, Switzerland) · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Titilope M DokunmuDepartment of Biochemistry, Covenant University, Ota, 23401, Nigeria.
Cynthia U AdjekukorDepartment of Biochemistry, Covenant University, Ota, 23401, Nigeria.
Omolara F YakubuDepartment of Biochemistry, Covenant University, Ota, 23401, Nigeria.
Adetutu O BelloDepartment of Biological Sciences, Covenant University, Ota, 23401, Nigeria.
Jarat O AdekoyaDepartment of Biological Sciences, Covenant University, Ota, 23401, Nigeria.
Olugbenga AkinolaDepartment of Pharmacology and Therapeutics, University of Ilorin, Ilorin, 24003, Nigeria.
Emmanuel O AmooDemography and Social Statistics Unit, Department of Economics and Development Studies, Covenant University, Ota, 23401, Nigeria.
Abiodun H AdebayoDepartment of Biochemistry, Covenant University, Ota, 23401, Nigeria. abiodun.adebayo@covenantuniversity.edu.ng.
Covenant University · NGUniversity of Ilorin · NG

Funding

Covenant University CUCRID Publication support
6 · The paper itself

Abstract

backgroundMalaria eradication globally is yet to be achieved and transmission is sustained in many endemic countries. Plasmodium falciparum continues to develop resistance to currently available anti-malarial drugs, posing great problems for malaria elimination. This study evaluates the frequencies of asymptomatic infection and multidrug resistance-1 (mdr-1) gene mutations in parasite isolates, which form the basis for understanding persistently high incidence in South West, Nigeria.

methodsA total of 535 individuals aged from 6 months were screened during the epidemiological survey evaluating asymptomatic transmission. Parasite prevalence was determined by histidine-rich protein II rapid detection kit (RDT) in healthy individuals. Plasmodium falciparum mdr-1 gene mutations were detected by polymerase chain reaction (PCR) followed by restriction enzyme digest and electrophoresis to determine polymorphism in parasite isolates. Sequencing was done to confirm polymorphism. Proportions were compared using Chi-square test at p value < 0.05.

resultsMalaria parasites were detected by RDT in 204 (38.1%) individuals. Asymptomatic infection was detected in 117 (57.3%) and symptomatic malaria confirmed in 87 individuals (42.6%). Overall, individuals with detectable malaria by RDT was significantly higher in individuals with symptoms, 87 of 197 (44.2%), than asymptomatic persons; 117 of 338 (34.6%), p = 0.02. In a sub-set of 75 isolates, 18(24%) and 14 (18.6%) individuals had Pfmdr1 86Y and 1246Y mutations.

conclusionsThere is still high malaria transmission rate in Nigeria with higher incidence of asymptomatic infections. These parasites harbour mutations on Pfmdr1 which contribute to artemisinin partner drug resistance; surveillance strategies to reduce the spread of drug resistance in endemic areas are needed to eliminate the reservoir of malaria parasites that can mitigate the eradication of malaria in Nigeria.

Indexed as

Asymptomatic InfectionsATP-Binding Cassette, Sub-Family C ProteinsIncidenceMalaria, FalciparumMutationNigeriaPlasmodium falciparumPrevalenceATP-Binding Cassette, Sub-Family C ProteinsMdr1 protein, Plasmodium falciparumAsymptomatic malariaDrug resistanceNigeriaPfmdr1Plasmodium falciparum

Identifiers

PMID31248414
PMCPMC6598231
OpenAlexW2954093007

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.